Considerations for the use of imaging tools for phase II treatment trials in oncology
AuthorsShankar, Lalitha K.
Van den Abbeele, Annick
FitzGerald, Thomas J.
MetadataShow full item record
AbstractIn the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.
SourceEpub 2009 Mar 10. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/46487
Related ResourcesLink to Article in PubMed